DDW 2015/EASL 2015: Statins Associated with Lower Risk of Death and Liver Decompensation
- Details
- Category: HCV Disease Progression
- Published on Monday, 18 May 2015 00:00
- Written by Liz Highleyman
Hepatitis C patients with liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of U.S. veterans presented at the Digestive Disease Week meeting this week in Washington, DC, and at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another recent study found that statins were associated with better response to hepatitis C treatment and lower risk of liver cancer.
More Articles...
- EASL 2015: Hepatitis C Treatment Effective for People with Advanced Liver Disease
- EASL 2015: Heavy Alcohol Use Is Strongest Predictor of Liver Damage and Death in French Hepatitis C Patients
- EASL 2015: Another Study Confirms Detrimental Effects of Delaying Hepatitis C Treatment
- EASL 2015: Advanced Liver Damage Is Common Among People with Undiagnosed Hepatitis C
- CROI 2015: Liver Disease Progression Is Common Among Baby Boomers with Hepatitis C
Web Design and Development by